Dr. Julie Ann Lough continues her conversation with Dr. Stephanie Mitchell, exploring Beckman Coulter's tools for monitoring antimicrobial resistance (AMR) and future innovations in the field. Dr. Mitchell discusses how antimicrobial susceptibility testing data can be aggregated into antibiograms to track resistance trends, inform therapy decisions, identify issues in infection control procedures, and potentially halt outbreaks before they spread. Dr. Mitchell shares insights on emerging technologies, including host response diagnostics to guide antibiotic prescribing, whole-genome sequencing for tracking plasmid transmission, and novel antimicrobials like phage therapy. The conversation addresses barriers to collaboration, the challenge of global data inequality in resource-limited regions, and the need for both prevention and treatment solutions. Dr. Mitchell closes with an inspiring message: taking many small steps together in the right direction will create meaningful change in the long term. The episode reinforces that AMR is a global problem requiring coordinated action from every sector, and Beckman Coulter remains committed to this mission daily.